Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Stomach Neoplasms × napabucasin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 4 Neoplasms by Site 3 Colorectal Neoplasms 3 Neoplasms, Glandular and Epithelial 2 Neoplasms by Histologic Type 2 Digestive System Neoplasms 2 Digestive System Diseases 2 Carcinoma, Non-Small-Cell Lung 2 Thymus Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Respiratory Tract Neoplasms 1 Rectal Diseases 1 Pancreatic Neoplasms 1 Pancreatic Diseases 1 Mesothelioma, Malignant 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Endocrine System Diseases 1 Endocrine Gland Neoplasms 1 Colonic Diseases 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Hepatocellular 1 Bronchial Neoplasms 1 Advanced Gastrointestinal Cancer 1

Interventions

Oxaliplatin 47 Cisplatin 43 Fluorouracil 42 Capecitabine 41 pembrolizumab 31 Leucovorin 28 Docetaxel 22 Irinotecan 19 Paclitaxel 18 Trastuzumab 17 Bevacizumab 12 Ramucirumab 11 Cetuximab 9 Radiotherapy 8 Surgical Procedures, Operative 7 Nivolumab 7 S 1 (combination) 6 Epirubicin 6 Carboplatin 6 Sunitinib 4 Platinum 4 Mitomycin 4 trastuzumab deruxtecan 3 olaparib 3 epacadostat 3 bemarituzumab 3 Pemetrexed 3 Ipilimumab 3 Folfox protocol 3 Everolimus 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02178956 2023-11-15

BRIGHTER

Sumitomo Pharma America, Inc.

Phase 3 Completed

714 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡